This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?
by Ekta Bagri
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
LQDAPositive Net Change JNJNegative Net Change UTHRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
SNDKNegative Net Change LIONPositive Net Change PTGXPositive Net Change
biotechs
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
by Zacks Equity Research
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
CGONPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDAPositive Net Change
biotechs
Reasons Why Investors Should Consider Betting on PTC Stock Now
by Zacks Equity Research
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
PTCTPositive Net Change NVSPositive Net Change RHHBYPositive Net Change IONSNegative Net Change
biotechs
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
by Ekta Bagri
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
CYTKPositive Net Change BMYPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
by Sundeep Ganoria
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
BBIONegative Net Change AZNPositive Net Change PFEPositive Net Change
biotechs medical pharmaceuticals
Immunome Stock Up 32% in a Month: Here's What You Should Know
by Zacks Equity Research
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
IMNMPositive Net Change AMRNPositive Net Change PTCTPositive Net Change LQDAPositive Net Change
biotechs
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
by Zacks Equity Research
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
FBRXPositive Net Change NVAXPositive Net Change AMRNPositive Net Change LQDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
by Ahan Chakraborty
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
by Zacks Equity Research
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
UTHRPositive Net Change NBIXPositive Net Change AMRNPositive Net Change LQDAPositive Net Change
biotechs